Investor Presentation First Nine Months of 2022

4 Investor presentation First nine months of 2022 Novo NordiskⓇ Strategic Aspirations 2025 | Highlights first nine months of 2022 Purpose and sustainability (ESG) Commercial execution • Progress towards zero environmental impact Carbon emissions decreased by 18% vs 9M 2019 Adding value to society Positive EMA opinion on human insulin with more flexible storage options 35.7 million people treated with NN products (net increase of 1.8 million vs end of September 2021) Being recognised as a sustainable employer Share of women in VP+ positions increased to 38% from 36% in 9M 2021 Diabetes value market share increased by 1.7%-points to 31.6%1 Obesity care sales of DKK 11.4 billion (+75% at CER) Rare disease sales of DKK 15.7 billion (+2% at CER) therapeutic focus Innovation and Financials Light blue indicates developments in Q3 2022 Further raise innovation bar for Diabetes treatment Completion of phase 3a trials with QW insulin icodec Completion of phase 2 trial with CagriSema in T2D Phase 1 initiated with once-weekly oral semaglutide Develop superior treatment solutions for obesity Phase 3 initiated with CagriSema in people with obesity Strengthen and progress Rare disease pipeline . • • Concizumab phase 3 trial completed in people with HA and B with inhibitors and in people without inhibitors Phase 3a trial initiated with Mim8 in Haemophilia A Acquisition of Forma Therapeutics mainly within SCD Sales growth of 16% and Operating profit growth of 14% • • Sales in International Operations grew by 11% Sales in the US grew by 21% with 72% of sales coming from products launched since 2015 Gross margin positively impacted by continued productivity gains in Product Supply Free cash flow of DKK 62.5 billion and DKK 41.9 billion returned to shareholders during 9M 2022 1MAT (Moving annual total) value market share 9M: First nine months; EMA: European Medicines Agency; VP: Vice president; QD: Once-daily; QW: Once-weekly; CER: Constant exchange rates; T2D: Type 2 diabetes; HA: Haemophilia A; HB: Haemophilia B; SCD: Sickle Cell Disease Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth

View entire presentation